Semaglutide’s psychiatric links
The diabetes and obesity drug semaglutide does not increase the risk of an initial diagnosis of a neurological or psychiatric condition – in fact it lowers the risk, research shows. Read More...
Semaglutide
New kid on the block
In the battle of weight loss drugs, international researchers have found that tirzepatide - commonly sold under the names Mounjaro or Zepbound - does a better job of cutting the kilos than semaglutide among overweight and obese people. Read More...
RNA med versus a wonder drug
The discovery of roles for RNA has been described as biology’s ‘neutron moment’ and new research shows the RNA-based treatment plozarisan has a greater impact on triglycerides than the ‘wonder drug’ semaglutide. Read More...
Heart benefits from weight loss drug
People taking the drug semaglutide not only lost around 10% of their body weight but had cardiovascular benefits irrespective of their starting weight or the amount of weight lost, according to research. Read More...
Worry over compounded diabetes drug
The TGA and the FDA have raised concerns about compounded semaglutide, with both regulators receiving reports of adverse events following patients’ use of semaglutide-like products. Read More...
Weight loss drug’s new side effects
A family of diabetes drugs that includes Ozempic is associated with an increased risk of gastrointestinal issues, according to international research published in JAMA, under the auspices of the American Medical Association. Read More...
No insulin needed
Researchers from the US have found that after treatment with a drug typically used for Type 2 diabetes, newly diagnosed Type 1 diabetes patients required little to no insulin. Read More...